Abstract
目的
β细胞去分化是糖尿病β细胞丢失的关键病理机制之一。N-甲基-D-天冬氨酸(N-methyl-D-aspartate,NMDA)受体长时间激活在糖尿病发生和发展中扮演着重要角色,但其机制尚未完全阐明。本研究旨在探讨NMDA受体长时间激活对胰岛β细胞去分化的影响及其作用机制。
方法
将雄性C57BL/6小鼠随机分为正常对照组(Control组)和NMDA组,每天于小鼠腹腔注射NMDA(8 mg/kg体重)或同等体积生理盐水,连续注射6个月。第6个月末进行葡萄糖耐量试验及使用酸联免疫吸附试验(enzyme linked immunosorbent assay,ELISA)检测血清中胰岛素分泌情况,并取胰腺组织进行免疫荧光染色检测胰岛素(insulin)、胰高血糖素(glucagon)和增殖细胞核抗原(proliferating cell nuclear antigen,PCNA)表达情况;采用real-time PCR检测胰岛β细胞、α细胞及胰岛祖细胞标志物mRNA表达。用NMDA处理原代胰岛观察NMDA对胰岛β细胞去分化的影响,再在细胞水平使用核因子kappa-B(nuclear factor kappa-B,NF-κB)抑制剂BAY 11-7082,通过检测胰岛素分泌情况以及内分泌细胞标志物的表达探讨NMDA诱导胰岛β细胞去分化的机制。
结果
与对照组相比,NMDA处理组小鼠注射葡萄糖后各个时间点的血糖值均增高,且糖耐量曲线下面积显著增加(均P<0.05)。NMDA组小鼠在葡萄糖注射后30 min血清中insulin含量以及胰岛素刺激指数显著低于对照组(均P<0.05)。Insulin与glucagon免疫双荧光染色结果显示:小鼠腹腔注射NMDA 6个月后,小鼠胰腺组织中insulin阳性的β细胞数量明显减少,而glucagon阳性的α细胞数量明显增加。Real-time PCR结果显示,腹腔注射NMDA 6个月后,小鼠胰腺组织中β细胞标志物(Insulin、Pdx1、Neurod1和Mafa)显著下调,而胰腺祖细胞标志物(Neurog3、Gata6、Hnf4a、Notch1和Hes1)和α细胞标志物(Glucagon、Arx、Irx2、Mafb、Pou6f2、Fev、Kcnj3和Sv2b)显著上调。NMDA处理原代小鼠胰岛48 h可以诱导β细胞标志基因表达显著下调(P<0.05或P<0.01),伴随着胰腺祖细胞标记物和α细胞标志物的显著上调(P<0.05,P<0.05或P<0.001)。NF-κB抑制剂BAY 11-7082能显著减轻NMDA处理胰岛48 h后β细胞标志物表达的下降(均P<0.05)和胰岛α细胞和胰腺祖细胞标志物表达的上调(P<0.05或P<0.01)。
结论
NMDA受体长时间激活诱导胰岛β细胞去分化,其机制有赖于NF-κB的介导。
Keywords: 胰岛β细胞, N-甲基-D-天冬氨酸, 细胞分化, 核因子kappa-B
Abstract
Objective
The β-cell dedifferentiation is one of the critical mechanisms in diabetic β-cell loss. Long-term activation of N-methyl-D-aspartate (NMDA) receptors plays an essential role in the development of diabetes, but the underlying mechanisms have not been fully elucidated. This study aims to investigate the effect of prolonged activation of NMDA receptors on islet β-cell dedifferentiation.
Methods
Male C57BL/6 mice were randomly divided into a normal control group (control group) and an NMDA group. The mice in the NMDA group were intraperitoneally injected with NMDA (8 mg/kg body weight) and those in the control group were injected with the same volume of saline every day for 6 months. At the end of the 6th month, glucose tolerance and enzyme linked immunosorbent assay (ELISA) were used to detect the function of islets, and pancreatic tissues were taken for immunofluorescence staining to detect the expressions of insulin, glucagon, and proliferating cell nuclear antigen (PCNA). Real-time PCR was used to detect the mRNA expression of pancreatic β cells, α cells, and islet progenitor cell markers.The primary islets were treated with NMDA to observe the effect of NMDA on the dedifferentiation of β cells. The nuclear factor kappa-B (NF-κB) inhibitor BAY 11-7082 was used at the cellular level via detecting insulin secretion and the expression of endocrine cell markers.
Results
Compared with the control group, the mice in the NMDA group had higher blood glucose levels at each time point after glucose injection, and the area under the glucose tolerance curve was significantly increased (P<0.05). The serum insulin content and insulin stimulatory index of the mice in the NMDA group were significantly lower than those in the control group at 30 min after glucose injection (both P<0.05). The double immunofluorescence staining for insulin and glucagon showed that the number of insulin-positive β cells in the pancreatic tissues of mice was significantly decreased after intraperitoneal injection of NMDA in mice for 6 months, while the number of glucagon-positive α cells was significantly increased. Real-time PCR results showed that β-cell markers (Insulin, Pdx1, Neurod1, and Mafa) were significantly down-regulated in mouse pancreatic tissues after intraperitoneal injection of NMDA for 6 months, while pancreatic progenitor cell markers (Neurog3, Gata6, Hnf4a, Notch1, and Hes1) were significantly down-regulated; α-cell markers (Glucagon, Arx, Irx2, Mafb, Pou6f2, Fev, Kcnj3, and Sv2b) were significantly up-regulated. NMDA treatment of mouse primary islets for 48 h cause significant down-regulation of β-cell marker gene expression (P<0.05 or P<0.01), accompanied by significant up-regulation of pancreatic progenitor cell markers and α-cell markers (P<0.05, P<0.01 or P<0.001). The NF-κB inhibitor BAY 11-7082 significantly blocked the down-regulation of β-cell marker expression (all P<0.05) and the up-regulation of α-cell and pancreatic progenitor cell marker after NMDA treatment of islets for 48 h (P<0.05 or P<0.01).
Conclusion
Prolonged activation of NMDA receptors induces islet β-cell dedifferentiation via regulating the NF-κB pathway.
Keywords: islet β cell, N-methyl-D-aspartate, cell differentiation, nuclear factor kappa-B
糖尿病是一种全身性的慢性代谢性疾病。过去的数十年里,糖尿病发病率急剧上升[1]。胰岛β细胞丢失被认为是糖尿病的关键病理改变之一[2-3]。近年来,谱系追踪实验显示β细胞丢失的主要原因并非细胞凋亡,而是β细胞的去分化[4-5]。β细胞去分化与转分化是指β细胞特异性基因(如胰岛素基因)表达的下调或缺失,伴随胰岛祖细胞标志物[如神经元素3(neurog3)]的上调和其他胰岛内分泌细胞标志物[如胰高血糖素(呈现“α样”细胞)][4]。β细胞去分化与转分化是糖尿病β细胞丢失的关键病理机制[4, 6-8]。长时间高血糖和胰岛慢性炎症引起的氧化应激与内质网应激可导致β细胞去分化[9-10];肾素-血管紧张素系统的激活通过核因子kappa-B (nuclear factor kappa-B,NF-κB)信号通路诱导β细胞去分化,最终导致β细胞丢失[11]。然而,β细胞去分化与转分化的机制尚未完全阐明。因此,对β细胞去分化与转分化机制的研究将有助于全面阐述糖尿病的发病机制,并为其防治提供新思路。
N-甲基-D-天冬氨酸(N-methyl-D-aspartate,NMDA)受体是重要的离子型谷氨酸受体。在中枢神经系统中NMDA受体过度激活会引起兴奋性神经毒性作用[12]。Nature Medicine [13]报道长期使用NMDA受体拮抗剂右美沙芬可以改善糖尿病小鼠的胰岛素分泌,缓解β细胞数量的减少。本课题组已报道NMDA受体拮抗剂美金刚胺可以减轻小鼠2型糖尿病,且长时间NMDA受体激活通过诱导内质网应激导致β细胞胰岛素分泌下降[14-15]。以上均提示NMDA受体激活在糖尿病发生和发展中扮演着重要角色,但其机制有待深入研究。在本课题组既往研究[16]中观察到,NMDA受体长时间激活可以降低胰岛素和β细胞特异性标志物胰十二指肠同源异构体1(pancreatic and duodenal homeobox 1,Pdx1)基因的表达。因此,笔者推测NMDA受体的长时间激活可能与糖尿病胰岛β细胞去分化相关,值得深入研究。
本研究旨在探讨NMDA受体激活对胰岛β细胞去分化的作用及机制,丰富糖尿病胰岛β细胞去分化的病理机制,为确证NMDA受体是糖尿病的治疗靶点提供理论依据。
1. 材料与方法
1.1. 动物
健康雄性C57BL/6小鼠(18~22 g),购自湖南斯莱克景达实验动物有限公司。实验动物饲养于中南大学湘雅医学院动物学部,饲养条件:室温22~24 ℃、湿度50%~60%、昼夜12 h节律。本研究获得中南大学动物学部伦理委员会批准(审批号:2013-07-11),实验过程中所有动物的处理均符合科技部2006年关于善待实验动物的规定。
1.2. 主要试剂
RPMI-1640和胎牛血清购于美国GIBCO公司;胶原酶Ⅴ、β巯基乙醇、青链霉素混合液购于美国Sigma-Aldrich公司;NF-κB抑制剂BAY 11-7802购于美国MCE公司;胰岛素酶联免疫吸附测定(enzyme linked immunosorbent assay,ELISA)试剂盒购自美国R&D公司;反转录试剂盒购自美国ThermoFisher 公司;TRIzol和SYBR Green试剂盒购自日本Takara公司;引物由生工生物工程(上海)有限公司合成,序列见表1。
表1.
定量PCR 引物序列
Table 1 Sequences of primers for real-time PCR
| Gene name | Primer sequence (5'-3') | |
|---|---|---|
| Forward | Reverse | |
| β-actin | GCTGTGCTATGTTGCTCTAGACT | GTTGGCATAGAGGTCTTTACGGA |
| Insulin | AGACCATCAGCAAGCAGGTC | ACACACCAGGTAGAGAGCCT |
| Neurod1 | GCTCCAGGGTTATGAGATCGT | TGAGACACTCATCTGTCCAGC |
| Nkx6.1 | GCTTGGCCTATTCTCTGGGGAT | TCCGAGTCCTGCTTCTTCTTGG |
| Glucagon | GGAACAACATTGCCAAACGTCA | GAAGTCCCTGGTGGCAAGATTA |
| Mafb | GAGGACCGCTTCTCTGATGAC | TCTCCAGGTGATGTTTCTGCTG |
| Arx | GCCTTCATCAGCCCAGCATTT | AGGATGTTGAGCTGCGTGAG |
| Neurog3 | TCTCAAGCATCTCGCCTCTTC | ACAGCAAGGGTACCGATGAGA |
| Pdx1 | ACACAGCTCTACAAGGACCC | ACTTCCCTGCTCCAGTGATC |
| Mafa | CTGCCTCCGTTTACTTGCTC | GGTTCCTCCGGGTTTTCTAA |
| Gata6 | GAGCTGGTGCTACCAAGAGG | TGCAAAAGCCCATCTCTTCT |
| Hnf4a | AGAGGTTCTGTCCCAGCAGA | ATGTACTTGGCCCACTCGAC |
| Notch1 | ACCCACTCTGTCTCCCACAC | GCTTCCTTGCTACCACAAGC |
| Hes1 | CCCACCTCTCTCTTCTGACG | AGGCGCAATCCAATATGAAC |
| Irx2 | GGCTATTCTCCCTTCCCAAG | CAGTGCAGTGTGCATCCTCT |
| Pou6f2 | CATCGAGCAGGTATGCAGAA | CCTGAGGGGTGTGTGTTCTT |
| Fev | GCACCTCGTTATGACCCCTA | GGGAACGGCAGAGATGTTTA |
| Kcnj3 | ACCCTGGTGGATCTCAAGTG | GGGAGTGTAGTTGCCGACAT |
| Sv2b | TGTCAGAGCAACGTGAGGAT | TGCGACCTTGAATGGAGAGT |
1.3. 方法
1.3.1. 动物分组及处理
将雄性C57BL/6小鼠随机分为正常对照组(Control组)和NMDA受体激动组(NMDA组),每组30只。NMDA组小鼠于每天上午经腹腔注射NMDA受体激动剂NMDA(8 mg/kg),Control组小鼠于每天上午经腹腔注射等量生理盐水。于第6个月末处死小鼠,取胰腺组织进行相关检测。
1.3.2. 小鼠糖耐量测定
小鼠经NMDA或生理盐水处理6个月后行腹腔注射葡萄糖耐量试验(intraperitoneal glucose tolerance test,IGTT):小鼠过夜禁食12 h,不禁水,葡萄糖剂量按2 mg/kg计算,于腹腔注射20%葡萄糖溶液。使用罗氏血糖仪,从尾静脉取血测定葡萄糖注射前以及注射后15、30、60和120 min的血糖值,计算葡萄糖曲线下面积(area under the curve,AUC),AUC=7.5×(0 min血糖+30 min血糖)+15×(15 min血糖+30 min血糖+60 min血糖)+30×(60 min血糖+120 min血糖)。
1.3.3. 免疫荧光技术
取胰腺组织经4%多聚甲醛固定24 h后,以乙醇梯度脱水,石蜡包埋后采用5 μm组织切片。将准备好的石蜡切片在温水中展开,用多聚赖氨酸包被的载玻片捞片,使石蜡切片平铺于载玻片上,在37 ℃下烘干。将烘干的切片依次浸于二甲苯、不同浓度乙醇、蒸馏水中。随后进行抗原修复,阻断内源性过氧化物酶,以BSA封闭,一抗(inuslin、glucagon和PCNA)、二抗孵育,染色等,最后置于显微镜下检查。
1.3.4. 小鼠胰岛的提取
于腹腔注射过量麻醉药戊巴比妥钠处死小鼠,找到胆总管,于胆总管近肝门处穿刺,向胰腺内灌注浓度为1 g/L的胶原酶Ⅴ,至胰腺完全膨胀,迅速分离胰腺,于37 ℃水浴20~25 min后使用预冷Hank’s液终止消化,待其分层后弃上层液体,使用预冷Hank’s液洗涤2次,手工挑拣胰岛备用[16]。
1.3.5. 细胞分组及处理
将细胞分成Control组和NMDA组。NMDA组用5 mmol/L NMDA处理胰岛48 h,然后收集上清和胰岛用于后续检测。
将细胞分成Control组、NMDA组和NMDA+BAY 11-7082组。NMDA+BAY 11-7082组使用10 μmol/L BAY11-7082预处理30 min,再使用5 mmol/L NMDA处理48 h;NMDA组使用5 mmol/L NMDA处理48 h。收集细胞用于检测。
1.3.6. 胰腺组织及胰岛RNA提取及基因水平检测
使用TRIzol法提取小鼠胰腺组织和胰岛的RNA,按照反转录试剂盒说明书将RNA反转录为cDNA,再进行real-time PCR,检测Insulin、Pdx1、Nkx6.1、Neurod1、Mafa、Neurog3、Gata6、Hnf4a、Notch1、Hes1、Irx2、Arx、Mafb、Pou6f2、Fev、Kcnj3以及Glucagon基因的表达情况。根据real-time PCR得出的荧光曲线的Ct值,以β-actin为内参,用2-ΔΔCt计算结果,实验结果以对照组的倍数表示。引物序列见表1。
1.3.7. 血清/细胞上清胰岛素含量测定
于小鼠眼球取血后,以2 500 r/min离心10 min,轻轻吸取上层血清待测。收集细胞上清液,以 800 r/min离心5 min后吸取上层上清液。采用ELISA试剂盒检测血清/细胞上清液中胰岛素的含量,将血清样本稀释10倍,其他操作参照产品说明书。胰岛素刺激指数(stimulatory index)=腹腔葡萄糖注射后30 min血清胰岛素含量/腹腔葡萄糖注射前(即0 min)血清胰岛素含量。
1.4. 统计学处理
采用SPSS 19.0统计软件进行数据的分析。检测结果采用均数±标准差( ±s)表示。两组样本均数比较采用非配对t检验,多组样本均数比较采用方差分析和LSD-t检验,以P<0.05为差异有统计学意义。
2. 结 果
2.1. NMDA对小鼠糖耐量和胰岛素分泌的影响
与对照组相比,NMDA组小鼠在注射葡萄糖后各个时间点的血糖值均增高(P<0.05、P<0.01或P<0.001;图1A),同时AUC亦显著增加(P<0.01,图1B)。本实验进一步检测葡萄糖刺激胰岛素的分泌情况,结果显示:NMDA组小鼠在葡萄糖注射后 30 min血清中胰岛素含量(P<0.01)以及胰岛素刺激指数(P<0.05)显著低于对照组(图1C,1D)。
图1.
NMDA对小鼠糖耐量和胰岛素分泌的影响
Figure 1 Effect of NMDA on the glucose tolerance and insulin secretion
A: Glucose concentrations in blood collected from the tail 0, 15, 30, 60, and 120 min after intraperitoneal injection; B: Area under the curve (AUC) of glucose tolerance after glucose injection; C: Insulin secretion measured before (0 min) and 30 min after glucose injection; D: Ratio of secreted insulin at 30 min to that secreted at 0 min (stimulatory index). *P<0.05, **P<0.01, and ***P<0.001 vs the Control group. NMDA: N-methyl-D-aspartate.
2.2. NMDA对小鼠胰腺组织中β细胞和α细胞数量的影响
Insulin与glucagon免疫双荧光染色结果显示:腹腔注射NMDA6个月后,小鼠胰腺组织中insulin阳性的β细胞数量明显减少,而glucagon阳性的α细胞数量明显增加(均P<0.05,图2A~2D)。进一步使用glucagon与PCNA免疫双荧光染色,NMDA组小鼠胰腺组织中glucagon阳性的α细胞反映细胞增殖活性的PCNA染色为阴性(图2E)。
图2.
NMDA对小鼠胰腺组织中β细胞和α细胞数量的影响
Figure 2 Effect of NMDA on the β cell mass and α cell mass
A: Immunofluorescence staining of insulin (red) and glucagon (green) (×200); B-C: Quantitative analysis of insulin and glucagon positive cell; D: Ratio of α cell and α cell+β cell; E: Immunofluorescence staining of PCNA (green) and glucagon (red) (×200). **P<0.01 vs the Control group. NMDA: N-methyl-D-aspartate; PCNA: Proliferating cell nuclear antigen; DAPI:4',6-diamidino-2-phenylindole.
2.3. NMDA对小鼠胰腺组织β细胞、α细胞和胰腺
祖细胞标志物表达的影响
Real-time PCR结果显示:腹腔注射NMDA 6个月后,小鼠胰腺组织中β细胞标志物(Insulin、Pdx1、Neurod1和Mafa)显著下调,而胰腺祖细胞标志物(Neurog3、Gata6、Hnf4a、Notch1和Hes1)和α细胞标志物(Glucagon、Arx、Irx2、Mafb、Pou6f2、Fev、Kcnj3和Sv2b)显著上调(图3)。
图3.
NMDA对小鼠胰腺组织β细胞、α细胞和胰腺祖细胞标志物表达的影响
Figure 3 Effect of NMDA on mRNA expression of β cell, α cell, and pancreatic progenitor cell markers in pancreatic tissues of mice
Heatmap of genes critical to endocrine cell. NMDA: N-methyl-D-aspartate.
2.4. NMDA对小鼠胰岛中β细胞、α细胞和胰腺祖细胞标志物表达的影响
进一步使用NMDA处理原代胰岛48 h后,发现NMDA组胰岛中β细胞标志物显著下调,而胰腺祖细胞标志物和α细胞标志物显著上调(P<0.05,P<0.01 或 P<0.001;图4A~4C)。
图4.
NMDA对小鼠胰岛中β细胞、α细胞和胰腺祖细胞标志物表达的影响
Figure 4 Effect of NMDA on mRNA expression of β cell, α cell, and pancreatic progenitor cell markers in primary islets of mice
A: Relative expression of genes involved in β cell identity; B: Relative expression of genes involved in progenitor cell identity; C: Relative expression of genes involved in α cell identity. *P<0.05, **P<0.01, and ***P<0.001. NMDA: N-methyl-D-aspartate.
2.5. NF-κB在NMDA诱导β细胞去分化中的作用
Real-time PCR结果显示:NF-κB抑制剂BAY 11-7082干预显著减轻NMDA处理胰岛48 h后β细胞标志物表达的下降(均P<0.05,图5A~5C)。同时BAY 11-7082干预显著降低NMDA处理所致胰岛α细胞和胰腺祖细胞标志物表达的上调(P<0.05或P<0.01,图5D~5H)。
图5.
NF-κB在NMDA诱导β细胞去分化中的作用
Figure 5 Role of NF-κB in dedifferentiation of β cell induced by NMDA
A-C: Relative expression of genes involved in β cell identity; D-E: Relative expression of genes involved in progenitor cell identity; F-G: Relative expression of genes involved in α cell identity; H: Insulin secretion during 1-hour incubation with 16.7 mmol/L glucose primary islets, normalized to insulin content. *P<0.05 and **P<0.01 vs the Control group; †P<0.05 and ††P<0.01 vs the NMDA group. NMDA: N-methyl-D-aspartate.
3. 讨 论
本研究从整体动物和离体细胞水平观察了NMDA受体长时间激活在胰岛β细胞去分化中的作用及机制,发现NMDA可激活胰岛β细胞中NF-κB通路进而诱导β细胞去分化,而使用NF-κB抑制剂可减轻NMDA诱导的β细胞去分化。本研究结果对于进一步揭示NMDA受体激活损伤胰岛β细胞的机制提供了实验依据。
近年研究显示外周非神经组织表达的NMDA受体激活参与一些疾病的发生发展,例如:肺动脉高压[12]、急性肺损伤[17]以及糖尿病[13, 18]。有趣的是,2型糖尿病小鼠长期使用NMDA受体拮抗剂可以改善胰岛素分泌、增加胰岛β细胞数量以及控制血糖[13, 18]。本研究结果发现经腹腔注射NMDA受体激动剂NMDA 6个月后小鼠的糖耐量明显增高、胰岛素分泌减少,胰岛β细胞减少,提示NMDA受体的长时间激活可以诱导小鼠胰岛β细胞的损伤,也进一步证实NMDA受体是治疗糖尿病的有效靶点。
本课题组已报道NMDA受体激活后,通过诱导内质网应激导致β细胞胰岛素分泌下降[14],并在整体水平上证实NMDA受体激活可以损伤小鼠糖耐量并减少胰岛素分泌[15]。但其机制仍有待深入研究。糖尿病β细胞丢失的关键病理机制之一是β细胞去分化[4, 6-8]。Cinti等[19]通过对15例2型糖尿病患者的胰岛进行分析,发现β细胞发生去分化,并部分转分化为“α样”和“δ样”细胞。β细胞去分化率与2型糖尿病的进展呈正相关[5]。然而,β细胞去分化的机制尚未完全阐明。本研究观察到腹腔注射NMDA 6个月的小鼠胰岛β细胞数量减少的同时伴随α细胞数量的增加,且α细胞的增加并非由细胞增殖所致。进一步real-time PCR结果显示NMDA处理后小鼠胰岛中β细胞标志物表达显著下调,而胰腺祖细胞标志物和α细胞标志物的表达显著上调。此外在原代胰岛上也得到了同样的结果。这些结果提示NMDA受体激活可诱导胰岛β细胞的去分化。
血管紧张素II介导胰岛β细胞去分化的作用依赖于NF-κB通路的激活[11]。本课题组前期已证实NMDA受体的长时间活化可以激活NF-κB,诱导 NF-κB p65的核转位[16, 18]。本研究发现抑制NF-κB可以显著逆转β细胞标志物表达显著下调,而胰腺祖细胞标志物和α细胞标志物的表达显著上调,提示NF-κB通路可能是NMDA诱导胰岛β细胞去分化的机制之一。
综上所述,NMDA受体长时间激活介导胰岛β细胞去分化,其机制有赖于NF-κB的介导。本研究进一步揭示了NMDA受体激活在糖尿病发生和发展中的作用及机制,为确证NMDA受体是糖尿病的治疗靶点提供了新的理论依据。本研究仅使用外源性NMDA受体激动剂NMDA证实NMDA受体长时间激活介导胰岛β细胞去分化的作用,下一步我们将在整体动物模型上特异性敲除胰岛β细胞NMDA受体以进一步证实NMDA受体在胰岛β细胞去分化中的作用。
基金资助
国家自然科学基金(82170853)。
This work was supported by the National Natural Science Foundation of China (82170853).
利益冲突声明
作者声称无任何利益冲突。
作者贡献
黄晓婷 动物及细胞实验,数据统计、分析,论文构想、撰写;熊大艳 动物及细胞实验;邓浪 数据统计、分析;唐四元、刘伟 论文审阅、修订。所有作者阅读并同意最终的文本。
原文网址
http://xbyxb.csu.edu.cn/xbwk/fileup/PDF/2022091182.pdf
参考文献
- 1. World Health Organisation . Diabetes [EB/OL]. (2021-11-10)[2022-03-01]. https://www.who.int/mediacentre/factsheets/fs312/en/.
- 2. Compston J. Type 2 diabetes mellitus and bone[J]. J Intern Med, 2018, 283(2): 140-153. 10.1111/joim.12725. [DOI] [PubMed] [Google Scholar]
- 3. Knudsen JG, Rorsman P. Β cell dysfunction in type 2 diabetes: drained of energy? [J]. Cell Metab, 2019, 29(1): 1-2. 10.1016/j.cmet.2018.12.015. [DOI] [PubMed] [Google Scholar]
- 4. Talchai C, Xuan S, Lin HV, et al. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure[J]. Cell, 2012, 150(6): 1223-1234. 10.1016/j.cell.2012.07.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Sun JJ, Ni QC, Xie J, et al. Β-cell dedifferentiation in patients with T2D with adequate glucose control and nondiabetic chronic pancreatitis[J]. J Clin Endocrinol Metab, 2019, 104(1): 83-94. 10.1210/jc.2018-00968. [DOI] [PubMed] [Google Scholar]
- 6. Zhang JJ, Liu F. The de-, re-, and trans-differentiation of β-cells: regulation and function[J]. Semin Cell Dev Biol, 2020, 103: 68-75. 10.1016/j.semcdb.2020.01.003. [DOI] [PubMed] [Google Scholar]
- 7. Efrat S. Beta-cell dedifferentiation in type 2 diabetes: concise review[J]. Stem Cells, 2019, 37(10): 1267-1272. 10.1002/stem.3059. [DOI] [PubMed] [Google Scholar]
- 8. Avrahami D, Wang YJ, Schug J, et al. Single-cell transcriptomics of human islet ontogeny defines the molecular basis of β-cell dedifferentiation in T2D[J]. Mol Metab, 2020, 42: 101057. 10.1016/j.molmet.2020.101057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Neelankal John A, Morahan G, Jiang FX. Incomplete re-expression of neuroendocrine progenitor/stem cell markers is a key feature of β-cell dedifferentiation[J]. J Neuroendocrinol, 2017, 29(1): 1-12. 10.1111/jne.12450. [DOI] [PubMed] [Google Scholar]
- 10. Hasnain SZ, Borg DJ, Harcourt BE, et al. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress[J]. Nat Med, 2014, 20(12): 1417-1426. 10.1038/nm.3705. [DOI] [PubMed] [Google Scholar]
- 11. Chen H, Zhou WJ, Ruan YT, et al. Reversal of angiotensin ll-induced β-cell dedifferentiation via inhibition of NF-κb signaling[J]. Mol Med, 2018, 24(1): 43. 10.1186/s10020-018-0044-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Dumas SJ, Bru-Mercier G, Courboulin A, et al. NMDA-type glutamate receptor activation promotes vascular remodeling and pulmonary arterial hypertension[J]. Circulation, 2018, 137(22): 2371-2389. 10.1161/CIRCULATIONAHA.117.029930. [DOI] [PubMed] [Google Scholar]
- 13. Marquard J, Otter S, Welters A, et al. Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment[J]. Nat Med, 2015, 21(4): 363-372. 10.1038/nm.3822. [DOI] [PubMed] [Google Scholar]
- 14. Huang XT, Liu W, Zhou Y, et al. Endoplasmic reticulum stress contributes to NMDA-induced pancreatic β-cell dysfunction in a CHOP-dependent manner[J]. Life Sci, 2019, 232: 116612. 10.1016/j.lfs.2019.116612. [DOI] [PubMed] [Google Scholar]
- 15. Huang XT, Yang JX, Wang Z, et al. Activation of N-methyl-D-aspartate receptor regulates insulin sensitivity and lipid metabolism[J]. Theranostics, 2021, 11(5): 2247-2262. 10.7150/thno.51666. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Huang XT, Yue SJ, Li C, et al. A sustained activation of pancreatic NMDARs is a novel factor of β-cell apoptosis and dysfunction[J]. Endocrinology, 2017, 158(11): 3900-3913. 10.1210/en.2017-00366. [DOI] [PubMed] [Google Scholar]
- 17. Li Y, Liu Y, Peng XP, et al. NMDA receptor antagonist attenuates bleomycin-induced acute lung injury[J/OL]. PLoS One, 2015, 10(5): e0125873 [2022-01-28]. 10.1371/journal.pone.0125873. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Huang XT, Li C, Peng XP, et al. An excessive increase in glutamate contributes to glucose-toxicity in β-cells via activation of pancreatic NMDA receptors in rodent diabetes[J]. Sci Rep, 2017, 7: 44120. 10.1038/srep44120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Cinti F, Bouchi R, Kim-Muller JY, et al. Evidence of β-cell dedifferentiation in human type 2 diabetes[J]. J Clin Endocrinol Metab, 2016, 101(3): 1044-1054. 10.1210/jc.2015-2860. [DOI] [PMC free article] [PubMed] [Google Scholar]





